HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cascara sagrada laxatives

This article was originally published in The Tan Sheet

Executive Summary

FDA will not defer enforcement action against manufacturers of OTC laxatives containing cascara sagrada, agency states in Sept. 2 letter to Atlanta law firm Arnall Golden Gregory denying citizen petition. Decision barring laxatives containing ingredient from initial entry into interstate commerce as of Nov. 5, 2002 stands, FDA says. Agency reply follows recent letter to AHPA denying association's request to move cascara sagrada from Category III to Category I (1"The Tan Sheet" Aug. 4, 2003, p. 11)...

You may also be interested in...



Aloe, Cascara Sagrada Safety In Laxatives Still Needs Supporting Data – FDA

Data on aloe and cascara sagrada from the German Commission E monographs, World Health Organization reviews and the National Toxicology Program are insufficient to support the safety and efficacy of the ingredients in OTC laxatives, FDA concludes in a July 3 letter to the American Herbal Products Association

Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round

Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.

Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children

Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS128675

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel